

23rd December 2022

ARKANSAS HEART HOSPITAL (AHH) COMMENCES PATIENTS ON wheezo® REMOTE PATIENT MONITORING (RPM) PROGRAM.

Highlights:

- Respiri and Access Telehealth RPM, under the supervision of AHH, commence enrolment of patients with Chronic Obstructive Pulmonary Disease (COPD) on the wheezo® RPM program.
- RPM Current Procedural Terminology (CPT) reimbursement claims and revenues to be processed within the next few months.
- Respiri to receive recurring revenues per patient per month in addition to the device sales.

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health management is pleased to announce that Arkansas Heart Hospital (AHH) have identified a target Chronic Obstructive Pulmonary Disease (COPD) patient population and commenced enrolment of patients into the wheezo® RPM program. This new patient benefit improves the standard of care for Cardiovascular Disease (CVD) patients that also have COPD, a common co-morbidity that complicates the management of these very high-risk patients.

The program was secured with our RPM partner Access Telehealth under the full-service premium model that includes patient engagement and remote monitoring using their cloud-based platform, Remotli. The wheezo® RPM program as an important clinical addition to patient management aimed to reduce avoidable hospital re-admissions that place a healthcare resource and economic burden on medical institutions. A reported 39%¹ of patients with CVD also have Chronic Obstructive Pulmonary Disease (COPD) which is a key contributor to hospital re-admissions. The objective is for the wheezo® RPM program to be a lifelong practice for patients.

RPM Current Procedural Terminology (CPT) reimbursement codes from this program will be processed through Centers for Medicare and Medicaid Services (CMS) and private insurers within the next few months.

The expedited commencement of the wheezo® RPM by AHH will provide an important clinical tool to physicians and medical staff aimed at improving the health of patients, reduce hospital readmissions and associated costs, and provide an improvement in allocation of resources by AHH as the program will not add to current workloads, a factor which often hampers new program roll out in healthcare organisations.

AHH was founded in 1997 by a group of patient-centric cardiologists led by Dr. Bruce Murphy. AHH is a 112-bed facility staffed with 9 cardiologists, many other specialties physicians, some 875 staff and with a respiratory/sleep laboratory and a number of outpatient clinics across Arkansas. With an extensive referral network, AHH is one of the largest private cardiovascular healthcare organisations in the USA, servicing tens of thousands of patients, providing almost 22,000 annual patient days of care, in addition to outpatient services, equating to almost USD\$648M in annual patient care billings.

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

AHH holds a 5 Star, Center for Medicare & Medicaid Services (CMS) rating and is one of the country's largest private providers of CVD care. CMS rates more than 4,500 hospitals throughout the United States and AHH has received the 5-Star rating, the highest accolade, and is also the only hospital in Arkansas recognized for its commitment to outstanding patient care for two years in a row.

Marjan Mikel, CEO of RespiRI said, "This is an exciting phase for RespiRI as we continue to grow our momentum with many US healthcare organisations and continue to broaden our footprint. The wheezo® RPM program is key to an expedited roll out as it improves healthcare management of patients and Access Telehealth make it relatively easy for our RPM clients. The Arkansas Heart Hospital experience is testament to this model."

RespiRI together with Access Telehealth are in advanced discussions with a number of other potential wheezo® RPM customers who have recognised the benefits of introducing RPM services as part of patient standard of care.

1. Defining the relationship between COPD and CVD: what are the implications for clinical practice? [Ther Adv Respir Dis](#). 2018 Jan-Dec; 12

Approved for release by the board of RespiRI Limited

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
RespiRI Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
RespiRI Limited
P: +61 447 074 160
E: nicholas@respiri.co

wheezo® is a registered trademark of RespiRI Limited.

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

About Respi Limited

Respi Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezo®, is an FDA cleared Class II Medical Device, the respi™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respi Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respi Limited please visit our corporate website www.respi.co/au

About wheezo®

Developed in Australia, with the support of an international panel leading respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the intuitive mobile application engages patients to log symptoms and triggers to build a personal profile to share data with healthcare providers so patients and physicians can have more informed discussions in relation to symptoms. The platform has been designed to extend care beyond the clinic which may lead to better health outcomes and improved quality of life for patients.

For information about our product offering in the US including wheezo® please visit www.respi.co/us

wheezo® is a registered trademark of Respi Limited.

About Access Telehealth

Access Telehealth is a digital health company dedicated to delivering innovative connected care solutions for management of people living with chronic disease. The Remotli platform uniquely simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance. Automated care-time tracking, and reimbursement reports makes it easy to boost revenue to support vital chronic disease management programs including Remote Physiologic Monitoring, Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more. Focusing on Remote Physiologic Monitoring and virtual care initiatives, the Access Telehealth clinical team delivers patient-centric remote monitoring services to support disease specific chronic care programs for health systems, payors, and providers, to enhance care delivery. www.accessrpm.com/

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respi only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.